nach oben

Journal of Hematopathology

Erschienen in:

01.09.2015 | Original Article

Molecular characterization and testing in acute myeloid leukemia

verfasst von: Gerald B. W. Wertheim

Erschienen in: Journal of Hematopathology | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Acute myeloid leukemia (AML) is a clinically and biologically heterogeneous group of neoplasms found in both the adult and pediatric populations. Many of the mutations that underlie AML pathogenesis have been elucidated and include both large-scale genomic events such as chromosomal additions, deletions, and translocations, as well as small-scale point mutations in tumorigenic genes. As patient prognosis and therapeutic decisions are largely determined by these genetic events, multifaceted genetic analysis of tissue sample from AML patients is required for proper diagnosis. Thus, an understanding of both the genetic events associated with AML and the testing modalities that assess these aberrations is essential for appropriate sample evaluation. Additionally, recognition of the molecular differences between adult and pediatric AML may provide insights into critical pathways involved in AML pathogenesis.

Deschler B, Lubbert M (2006) Acute myeloid leukemia: epidemiology and etiology. Cancer 107(9):2099–2107PubMed

Meshinchi S, Arceci RJ (2007) Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia. Oncologist 12(3):341–355PubMed

Pui CH et al (2011) Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol 29(5):551–565PubMedCentralPubMed

Tasian SK, Pollard JA, Aplenc R (2014) Molecular therapeutic approaches for pediatric acute myeloid leukemia. Front Oncol 4:55PubMedCentralPubMed

Bitter MA et al (1987) Associations between morphology, karyotype, and clinical features in myeloid leukemias. Hum Pathol 18(3):211–225PubMed

Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman J (2008) WHO classification of tumours of haematopoietic and lymphoid tissue. International Agency for Research on Cancer, Lyon

Bennett JM et al (1976) Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 33(4):451–458PubMed

Burke MJ et al (2014) Similar outcomes between adolescent/young adults and children with AML following allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 49(2):174–178PubMed

Canner J et al (2013) Differences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients: a report from the Children’s Oncology Group. Cancer 119(23):4162–4169PubMedCentralPubMed

10.

Grimwade D et al (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The medical research council adult and children’s leukaemia working parties. Blood 92(7):2322–2333

11.

Deguchi K, Gilliland DG (2002) Cooperativity between mutations in tyrosine kinases and in hematopoietic transcription factors in AML. Leukemia 16(4):740–744PubMed

12.

Kelly LM, Gilliland DG (2002) Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet 3:179–198PubMed

13.

Dombret H (2011) Gene mutation and AML pathogenesis. Blood 118(20):5366–5367PubMed

14.

The Cancer Genome Atlas Research Network (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med, 368(22): 2059-2074

15.

Patel JP et al (2012) Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 366(12):1079–1089PubMedCentralPubMed

16.

Rocquain J et al (2010) Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer 10:401PubMedCentralPubMed

17.

Wertheim GB, Hexner E, Bagg A (2012) Molecular-based classification of acute myeloid leukemia and its role in directing rational therapy: personalized medicine for profoundly promiscuous proliferations. Mol Diagn Ther 16(6):357–369PubMed

18.

Ley TJ et al (2010) DNMT3A mutations in acute myeloid leukemia. N Engl J Med 363(25):2424–2433PubMedCentralPubMed

19.

Mardis ER et al (2009) Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361(11):1058–1066PubMedCentralPubMed

20.

Tallman MS (1994) All-trans-retinoic acid in acute promyelocytic leukemia and its potential in other hematologic malignancies. Semin Hematol 31(4 Suppl 5):38–48PubMed

21.

Labrecque J et al (1998) Impaired granulocytic differentiation in vitro in hematopoietic cells lacking retinoic acid receptors alpha1 and gamma. Blood 92(2):607–615PubMed

22.

Purton LE et al (2006) RARgamma is critical for maintaining a balance between hematopoietic stem cell self-renewal and differentiation. J Exp Med 203(5):1283–1293PubMedCentralPubMed

23.

Sanz MA et al (2010) Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood 115(25):5137–5146PubMed

24.

Grimwade D et al (2010) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116(3):354–365PubMed

25.

Redner RL et al (1996) The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood 87(3):882–886PubMed

26.

Wells RA, Catzavelos C, Kamel-Reid S (1997) Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia. Nat Genet 17(1):109–113PubMed

27.

Rohr SS et al (2012) Acute promyelocytic leukemia associated with the PLZF-RARA fusion gene: two additional cases with clinical and laboratorial peculiar presentations. Med Oncol 29(4):2345–2347PubMed

28.

Sainty D et al (2000) A new morphologic classification system for acute promyelocytic leukemia distinguishes cases with underlying PLZF/RARA gene rearrangements. Blood 96(4):1287–1296PubMed

29.

Arnould C et al (1999) The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia. Hum Mol Genet 8(9):1741–1749PubMed

30.

Harrison CJ et al (2010) Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol 28(16):2674–2681PubMed

31.

Rubnitz JE et al (2010) Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol 11(6):543–552PubMedCentralPubMed

32.

von Neuhoff C et al (2010) Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol 28(16):2682–2689

33.

Morrissette JJ, Bagg A (2011) Acute myeloid leukemia: conventional cytogenetics, FISH, and moleculocentric methodologies. Clin Lab Med 31(4):659–686, xPubMed

34.

Walter K et al (2010) Aberrant expression of CD19 in AML with t(8;21) involves a poised chromatin structure and PAX5. Oncogene 29(20):2927–2937PubMed

35.

Schwyzer R et al (1998) Granulocytic sarcoma in children with acute myeloblastic leukemia and t(8;21). Med Pediatr Oncol 31(3):144–149PubMed

36.

Tallman MS et al (1993) Granulocytic sarcoma is associated with the 8;21 translocation in acute myeloid leukemia. J Clin Oncol 11(4):690–697PubMed

37.

Larson RA et al (1986) Acute myelomonocytic leukemia with abnormal eosinophils and inv(16) or t(16;16) has a favorable prognosis. Blood 68(6):1242–1249PubMed

38.

Le Beau MM et al (1983) Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia. A unique cytogenetic-clinicopathological association. N Engl J Med 309(11):630–636PubMed

39.

Paschka P et al (2006) Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 24(24):3904–3911PubMed

40.

Pollard JA et al (2010) Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood 115(12):2372–2379PubMedCentralPubMed

41.

Tarlock K et al (2014) Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: a report from the Children’s Oncology Group. Br J Haematol 166(2):254–259PubMedCentralPubMed

42.

Alsabeh R et al (1997) Acute myeloid leukemia with t(6;9) (p23;q34): association with myelodysplasia, basophilia, and initial CD34 negative immunophenotype. Am J Clin Pathol 107(4):430–437PubMed

43.

Hoyle CF, Sherrington P, Hayhoe FG (1988) Translocation (3;6)(q21;p21) in acute myeloid leukemia with abnormal thrombopoiesis and basophilia. Cancer Genet Cytogenet 30(2):261–267PubMed

44.

Groschel S et al (2014) A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia. Cell 157(2):369–381PubMed

45.

Yamazaki H et al (2014) A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression. Cancer Cell 25(4):415–427PubMedCentralPubMed

46.

Balgobind BV et al (2010) EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia. Leukemia 24(5):942–949PubMed

47.

Groschel S et al (2010) High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J Clin Oncol 28(12):2101–2107PubMed

48.

Groschel S et al (2013) Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group. J Clin Oncol 31(1):95–103PubMed

49.

Lugthart S et al (2010) Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J Clin Oncol 28(24):3890–3898PubMed

50.

de Rooij JD et al (2013) NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern. Leukemia 27(12):2280–2288PubMed

51.

Gruber TA et al (2012) An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. Cancer Cell 22(5):683–697PubMedCentralPubMed

52.

Masetti R et al (2013) CBFA2T3-GLIS2 fusion transcript is a novel common feature in pediatric, cytogenetically normal AML, not restricted to FAB M7 subtype. Blood 121(17):3469–3472PubMed

53.

Tamai H, Inokuchi K (2010) 11q23/MLL acute leukemia : update of clinical aspects. J Clin Exp Hematop 50(2):91–98PubMed

54.

Krivtsov AV, Armstrong SA (2007) MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 7(11):823–833PubMed

55.

Balgobind BV et al (2009) Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood 114(12):2489–2496PubMedCentralPubMed

56.

Rubnitz JE et al (2002) Favorable impact of the t(9;11) in childhood acute myeloid leukemia. J Clin Oncol 20(9):2302–2309PubMed

57.

Braoudaki M, Tzortzatou-Stathopoulou F (2012) Clinical cytogenetics in pediatric acute leukemia: an update. Clin Lymphoma Myeloma Leuk 12(4):230–237PubMed

58.

Akiki S et al (2013) NUP98-NSD1 fusion in association with FLT3-ITD mutation identifies a prognostically relevant subgroup of pediatric acute myeloid leukemia patients suitable for monitoring by real time quantitative PCR. Genes Chromosom Cancer 52(11):1053–1064PubMed

59.

Hollink IH et al (2011) NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood 118(13):3645–3656PubMed

60.

Jaju RJ et al (2001) A novel gene, NSD1, is fused to NUP98 in the t(5;11)(q35;p15.5) in de novo childhood acute myeloid leukemia. Blood 98(4):1264–1267PubMed

61.

Coenen EA et al (2013) Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Munster AML-study group. Blood 122(15):2704–2713PubMedCentralPubMed

62.

Hui CH, Suttle J (2001) Erythrophagocytosis associated with AML-M5 and t(8;16). Br J Haematol 113(4):845PubMed

63.

Breems DA et al (2008) Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol 26(29):4791–4797PubMed

64.

Kayser S et al (2012) Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies. Blood 119(2):551–558PubMed

65.

van den Heuvel-Eibrink MM et al (2001) MDR1 expression in poor-risk acute myeloid leukemia with partial or complete monosomy 7. Leukemia 15(3):398–405PubMed

66.

Hasle H et al (2007) Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. Blood 109(11):4641–4647PubMed

67.

Watt CD, Bagg A (2010) Molecular diagnosis of acute myeloid leukemia. Expert Rev Mol Diagn 10(8):993–1012PubMed

68.

Wolff DJ et al (2007) Guidance for fluorescence in situ hybridization testing in hematologic disorders. J Mol Diagn 9(2):134–143PubMedCentralPubMed

69.

Frohling S et al (2005) Diagnostic value of fluorescence in situ hybridization for the detection of genomic aberrations in older patients with acute myeloid leukemia. Haematologica 90(2):194–199PubMed

70.

Zordan A (2011) Fluorescence in situ hybridization on formalin-fixed, paraffin-embedded tissue sections. Methods Mol Biol 730:189–202PubMed

71.

Loken MR et al (2012) Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children’s Oncology Group. Blood 120(8):1581–1588PubMedCentralPubMed

72.

Bacher U et al (2009) Molecular diagnostics in acute leukemias. Clin Chem Lab Med 47(11):1333–1341PubMed

73.

King RL et al (2011) A comparative analysis of molecular genetic and conventional cytogenetic detection of diagnostically important translocations in more than 400 cases of acute leukemia, highlighting the frequency of false-negative conventional cytogenetics. Am J Clin Pathol 135(6):921–928PubMed

74.

Laforet MP et al (2013) Design and feasibility of a novel, rapid, and simple fluorescence 26-plex rt-PCR assay for simultaneous detection of 24 fusion transcripts in adult acute myeloid leukemia. J Mol Diagn 15(2):186–195PubMed

75.

Ye F, Laosinchai-Wolf W, Labourier E (2012) An optimized technology platform for the rapid multiplex molecular analysis of genetic alterations associated with leukemia. Cancer Genet 205(10):488–500PubMedCentralPubMed

76.

Marcucci G et al (2001) Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia. Leukemia 15(7):1072–1080PubMed

77.

Basecke J et al (2002) Transcription of AML1/ETO in bone marrow and cord blood of individuals without acute myelogenous leukemia. Blood 100(6):2267–2268PubMed

78.

Kusec R et al (1994) AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. Leukemia 8(5):735–739PubMed

79.

Miyamoto T, Weissman IL, Akashi K (2000) AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc Natl Acad Sci U S A 97(13):7521–7526PubMedCentralPubMed

80.

Wiemels JL et al (2002) In utero origin of t(8;21) AML1-ETO translocations in childhood acute myeloid leukemia. Blood 99(10):3801–3805PubMed

81.

Falini B et al (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352(3):254–266PubMed

82.

Colombo E et al (2005) Nucleophosmin is required for DNA integrity and p19Arf protein stability. Mol Cell Biol 25(20):8874–8886PubMedCentralPubMed

83.

Colombo E et al (2002) Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol 4(7):529–533PubMed

84.

Lindstrom MS (2011) NPM1/B23: a multifunctional chaperone in ribosome biogenesis and chromatin remodeling. Biochem Res Int 2011:195209PubMedCentralPubMed

85.

Falini B et al (2006) Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. Blood 108(6):1999–2005PubMed

86.

Pasqualucci L et al (2006) Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: impact on WHO classification. Blood 108(13):4146–4155PubMed

87.

Schnittger S et al (2005) Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 106(12):3733–3739PubMed

88.

Cazzaniga G et al (2005) Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. Blood 106(4):1419–1422PubMed

89.

Schlenk RF et al (2008) Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358(18):1909–1918PubMed

90.

Gale RE et al (2008) The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 111(5):2776–2784PubMed

91.

Brown P et al (2007) The incidence and clinical significance of nucleophosmin mutations in childhood AML. Blood 110(3):979–985PubMedCentralPubMed

92.

Yeamans C et al (2007) C/EBPalpha binds and activates the PU.1 distal enhancer to induce monocyte lineage commitment. Blood 110(9):3136–3142PubMedCentralPubMed

93.

Fos J et al (2011) Deficient CEBPA DNA binding function in normal karyotype AML patients is associated with favorable prognosis. Blood 117(18):4881–4884PubMed

94.

Dufour A et al (2010) Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol 28(4):570–577PubMed

95.

Paz-Priel I, Friedman A (2011) C/EBPalpha dysregulation in AML and ALL. Crit Rev Oncog 16(1–2):93–102PubMedCentralPubMed

96.

Matsuo H et al (2014) Prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group. Blood Cancer J 4:e226PubMedCentralPubMed

97.

Meshinchi S et al (2006) Clinical implications of FLT3 mutations in pediatric AML. Blood 108(12):3654–3661PubMedCentralPubMed

98.

Schnittger S et al (2002) Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 100(1):59–66PubMed

99.

Yamamoto Y et al (2001) Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97(8):2434–2439PubMed

100.

Kiyoi H et al (1998) Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 12(9):1333–1337PubMed

101.

Kottaridis PD et al (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98(6):1752–1759PubMed

102.

Thiede C et al (2006) Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 107(10):4011–4020PubMed

103.

Mead AJ et al (2008) Conflicting data on the prognostic significance of FLT3/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic disease. Blood 112(2):444–445, author reply 445PubMed

104.

Mead AJ et al (2007) FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood 110(4):1262–1270PubMed

105.

Kottaridis PD et al (2002) Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood 100(7):2393–2398PubMed

106.

Figueroa ME et al (2010) DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 17(1):13–27PubMedCentralPubMed

107.

Valk PJ et al (2004) Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 350(16):1617–1628PubMed

108.

Paschka P et al (2010) IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 28(22):3636–3643PubMed

109.

Figueroa ME et al (2010) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18(6):553–567PubMedCentralPubMed

110.

Ho PA et al (2011) Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children’s Oncology Group. Pediatr Blood Cancer 57(2):204–209PubMedCentralPubMed

111.

Liang DC et al (2013) Cooperating gene mutations in childhood acute myeloid leukemia with special reference on mutations of ASXL1, TET2, IDH1, IDH2, and DNMT3A. Blood 121(15):2988–2995PubMed

112.

Damm F et al (2011) Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups. Leukemia 25(11):1704–1710PubMed

113.

Markova J et al (2012) Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia. Eur J Haematol 88(2):128–135PubMed

114.

Ribeiro AF et al (2012) Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. Blood 119(24):5824–5831PubMed

115.

Delhommeau F et al (2009) Mutation in TET2 in myeloid cancers. N Engl J Med 360(22):2289–2301PubMed

116.

Gaidzik VI (2012) TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. J Clin Oncol 30(12):1350–1357PubMed

117.

Smith CC et al (2012) Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 485(7397):260–263PubMedCentralPubMed

118.

Wander SA, Levis MJ, Fathi AT (2014) The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond. Ther Adv Hematol 5(3):65–77PubMedCentralPubMed

119.

Russler-Germain DA et al (2014) The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer Cell 25(4):442–454PubMedCentralPubMed

120.

Dang L et al (2010) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 465(7300):966PubMedCentralPubMed

121.

Ward PS et al (2010) The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17(3):225–234PubMedCentralPubMed

122.

Kandoth C et al (2013) Mutational landscape and significance across 12 major cancer types. Nature 502(7471):333–339PubMedCentralPubMed

123.

Ottone T et al (2008) An allele-specific rt-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia. J Mol Diagn 10(3):212–216PubMedCentralPubMed

124.

Chang TL et al (2003) Simplified capillary electrophoresis detection of the Flt-3 internal tandem duplications and D835 point mutations in acute myeloid leukemia. Haematologica 88(2):ELT04PubMed

125.

Murphy KM et al (2003) Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. J Mol Diagn 5(2):96–102PubMedCentralPubMed

126.

White BS, DiPersio JF (2014) Genomic tools in acute myeloid leukemia: from the bench to the bedside. Cancer 120(8):1134–1144PubMedCentralPubMed

127.

Alvarez S et al (2010) DNA methylation profiles and their relationship with cytogenetic status in adult acute myeloid leukemia. PLoS One 5(8):e12197PubMedCentralPubMed

128.

Bullinger L et al (2010) Quantitative DNA methylation predicts survival in adult acute myeloid leukemia. Blood 115(3):636–642PubMed

129.

Zanotti L et al (2014) Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use. Tumour Biol 35(9):8461–8470

130.

Srivastava G et al (2014) Prospective multicenter study of the impact of oncotype DX colon cancer assay results on treatment recommendations in stage II colon cancer patients. Oncologist 19(5):492–497PubMedCentralPubMed

131.

Chatterton Z et al (2014) Validation of DNA methylation biomarkers for diagnosis of acute lymphoblastic leukemia. Clin Chem 60(7):995–1003PubMed

132.

Wertheim GB et al (2014) Microsphere-based multiplex analysis of DNA methylation in acute myeloid leukemia. J Mol Diagn 16(2):207–215PubMedCentralPubMed

133.

Rubnitz JE, Inaba H (2012) Childhood acute myeloid leukaemia. Br J Haematol 159(3):259–276PubMedCentralPubMed

134.

Schuback HL, Arceci RJ, Meshinchi S (2013) Somatic characterization of pediatric acute myeloid leukemia using next-generation sequencing. Semin Hematol 50(4):325–332PubMed

Titel: Molecular characterization and testing in acute myeloid leukemia
verfasst von: Gerald B. W. Wertheim
Publikationsdatum: 01.09.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Hematopathology / Ausgabe 3/2015
Print ISSN: 1868-9256
Elektronische ISSN: 1865-5785
DOI: https://doi.org/10.1007/s12308-015-0242-7

Springer Medizin

Molecular characterization and testing in acute myeloid leukemia

Abstract

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2015

Myeloproliferative neoplasms in children

Pediatric myelodysplastic syndromes

Deconstructing the diagnosis of hemophagocytic lymphohistiocytosis using illustrative cases

Paediatric hematopathology: something real special

Myeloid proliferations associated with Down syndrome

Pediatric myelodysplastic/myeloproliferative neoplasms and related diseases

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie